Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Agilent TechnologiesMEX:A 89 Return-on-Tangible-Asset is 16.95% as of Apr. 2026, which is 9% below its 10-year median of 18.71. GuruFocus rates MEX:A with a GF Score™ of 89/100 and a GF Value™ of MXN2,544.68 (Fairly Valued). The stock has 1 warning sign investors should review. Among 213 Medical Diagnostics & Research companies, Agilent Technologies ranks better than 91.08% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Agilent Technologies's annualizedNet Income for the quarter that ended in Apr. 2026 was MXN23,752 Mil. Agilent Technologies's average total tangible assets for the quarter that ended in Apr. 2026 was MXN140,144 Mil. Therefore, Agilent Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Apr. 2026 was 16.95%.
The historical rank and industry rank for Agilent Technologies's Return-on-Tangible-Asset or its related term are showing as below:
MEX:A'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6 Med: 18.71 Max: 22.11
Current: 18.43
During the past 13 years, Agilent Technologies's highest Return-on-Tangible-Asset was 22.11%. The lowest was 6.00%. And the median was 18.71%.
MEX:A's Return-on-Tangible-Asset is ranked better than 91.08% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs MEX:A: 18.43
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Agilent Technologies Return-on-Tangible-Asset Related Terms
Agilent Technologies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:A vs NTRA, WAT, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Apr. 2026) net income data.
What does a Return-on-Tangible-Asset of 16.95% mean?
Agilent Technologies (MEX:A) has a Return-on-Tangible-Asset of 16.95% as of Apr. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Agilent Technologies and its competitors. This is near median its historical median of 18.71. Over the past decade, Agilent Technologies' Return-on-Tangible-Asset has ranged from 6.00 to 22.11. According to the industry distribution chart, Agilent Technologies ranks #19 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 8.9%.
Is Agilent Technologies' Return-on-Tangible-Asset too high?
Agilent Technologies' current Return-on-Tangible-Asset of 16.95% is near median its 10-year median of 18.71. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 22.11. Based on the distribution chart, Agilent Technologies ranks #19 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Agilent Technologies has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' Return-on-Tangible-Asset compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #19 out of 213 companies for Return-on-Tangible-Asset. This places Agilent Technologies in the top 9% of its industry — outperforming the majority of peers. Historically, Agilent Technologies' own Return-on-Tangible-Asset has ranged from 6.00 to 22.11 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Agilent Technologies and its competitors. Agilent Technologies's current Return-on-Tangible-Asset is 16.95%, which is near median its own 10-year median of 18.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (MEX:A) is currently considered Fairly Valued. The stock's GF Value™ is MXN2,544.68, compared to a current price of MXN2,350.00 — trading 7.7% below its estimated fair value. The current Return-on-Tangible-Asset is 16.95%, which is near median its 10-year median of 18.71. Agilent Technologies' overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Agilent Technologies (MEX:A), the current Return-on-Tangible-Asset is 16.95% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (MEX:A) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of MXN2,350.00 is trading 7.7% below its estimated GF Value™ of MXN2,544.68.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for MEX:A:
Return-on-Tangible-Asset: 16.95% (near median its 10-year median of 18.71)
GF Value™: MXN2,544.68 vs. price of MXN2,350.00 (7.7% below fair value)
No single metric tells the full story. See the MEX:A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
89GF Score
Get the complete analysis for MEX:A
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:A has been successfully added to your 
